By IDSE News Staff
Moderna announced its investigational mRNA vaccine (mRNA-1345) targeting respiratory syncytial virus (RSV) in older adults has met the primary efficacy end points in a phase 3 trial.
The mRNA-1345 vaccine is formulated with the same mRNA technology used in the company’s COVID-19 vaccine (Spikevax). The mRNA-1345 vaccine works by encoding for a prefusion F glycoprotein, which then elicits a high neutralizing antibody response.
The ConquerRSV phase 3 pivotal efficacy trial